Citations

Mayo Clinic

Clear

1164 citation(s) found for "Yu, Victoria".

Establishing a Point-of-Care Virtual Planning and 3D Printing Program
Sears, Victoria A. , Morris, Jonathan M.

Seminars in Plastic Surgery | December 7, 2022 | Volume: 36 | Issue: 03 | Pages: 133-148

10.1055/s-0042-1754351 | PMID 36506280 Get It

Abstract Virtual surgical planning (VSP) and three-dimensional (3D) printing have become a standard of care at our institution, transforming the surgical care of complex patients. Patient-specific, anatomic models and surgical guides are clinically used to improve multidisciplinary communication, presurgical planning, intraoperative guidance, and the patient informed consent. Recent innovations have allowed both VSP and 3D printing to become more accessible to various sized hospital systems. Insourcing such work has several advantages including quicker turnaround times and increased innovation through collaborative multidisciplinary teams. Centralizing 3D printing programs at the point-of-care provides a greater cost-efficient investment for institutions. The following article will detail capital equipment needs, institutional structure, operational personnel, and other considerations necessary in the establishment of a POC manufacturing program.
Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association
Burch, Henry B. , Cooper, David S. , Dolman, Peter J. , Leung, Angela M. , Mombaerts, Ilse , Stan, Marius N. , Stan, Marius N , Leung, Angela M , Perros, Petros , Bednarczuk, Tomasz , Salvi, Mario

European Thyroid Journal | November 29, 2022 | Volume: 11 | Issue: 6 | Pages: No page available

10.1530/etj-22-0189 | PMID 36479875 Get It

Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this Consensus Statement.
Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
Trudel, Suzanne , Spencer, Andrew , Forsberg, Peter A. , Laubach, Jacob P. , Mateos, María‐Victoria , Kaedbey, Rayan , Krishnan, Amrita , Choeurng, Voleak, Cooper, James Fenimore, Sumiyoshi, Teiko, Wong, Chihunt, Lesokhin, Alexander M. , Richter, Joshua , Cohen, Adam D. , Thomas, Sheeba K. , Bahlis, Nizar Jacques , Costa, Luciano J. , Rodríguez‐Otero, Paula , Berdeja, Jesús G. , Fonseca, Rafaël , Harrison, Simon J

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4415-4417

10.1182/blood-2022-157547 Get It

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Kumar, Shaji , Leleu, Xavier , Manier, Salomon , Mateos, María‐Victoria , Bumma, Naresh , Gong, Weiying, Roy, Pourab, Lorenc, Karen Rodriguez , Kroog, Glenn S. , Sarkaria, Shawn , Rodríguez‐Otero, Paula , Joseph, Nisha S. , Lee, Hans C. , Dimopoulos, Meletios Α. , Oriol, Albert

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4444-4446

10.1182/blood-2022-157713 Get It

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
LaPlant, Betsy, Alegria, Victoria R., Elliott, Jamie, Sher, Taimur , Paulus, Aneel , Chapin, Dustin, Heslop, Keisha, Chanan‐Khan, Asher , Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4450-4451

10.1182/blood-2022-164656 Get It

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
Paulus, Aneel , LaPlant, Betsy, Alegria, Victoria R., Zimmerman, Ashley, Chapin, Dustin, Sher, Taimur , Chanan‐Khan, Asher , Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9904-9905

10.1182/blood-2022-164667 Get It

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Inte
Mian, Agrima , Yi, Jean C. , Preussler, Jaime M. , Hill, Brian T. , Černý, Jan , Deol, Abhinav , Hahn, Theresa , Hashmi, Shahrukh K. , Khera, Nandita , Loren, Alison W. , Stiff, Patrick J. , Uberti, Joseph P., Whalen, Victoria , Reynolds, Jana , Syrjala, Karen L. , Hamilton, Betty K. , Wei, Wei , Chakraborty, Rajshekhar , Jaglowski, Samantha , Jim, Heather , McGuirk, Joseph P. , Savani, Bipin N. , Wingard, John R. , Holtan, Shernan G. , Wood, William A. , Baker, Kevin Scott , Majhail, Navneet S.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8019-8021

10.1182/blood-2022-167411 Get It

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
LaPlant, Betsy, Alegria, Victoria R., Elliott, Jamie, Zimmerman, Ashley, Heslop, Keisha, Chapin, Dustin, Sher, Taimur , Rasheed, Ahsan , Paulus, Aneel , Chanan‐Khan, Asher , Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9331-9332

10.1182/blood-2022-165377 Get It

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
Pérez, Gabriela , Kharfan‐Dabaja, Mohamed A. , Ayala, Ernesto, O’Brien, Patrick, Alegria, Victoria R., Zimmerman, Ashley, Chapin, Dustin, Lanier, Stephanie, Kasik, Carly, Bradley, Schannon, Sher, Taimur , Paulus, Aneel , Chanan‐Khan, Asher , Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Murthy, Hemant S. , Roy, Vivek

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10165-10166

10.1182/blood-2022-165209 Get It